ANACETRAPIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H25F10NO3
Molecular Weight	637.5084
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC(F)=C(C=C1C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F)C(C)C

InChI

InChIKey=MZZLGJHLQGUVPN-HAWMADMCSA-N

InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1

HIDE SMILES / InChI

Description

Anacetrapib is a CETP inhibitor being developed by Merck to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor that blocks the transfer of cholesterol from highdensity lipoprotein to other lipoproteins. This results in an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in lowdensity lipoprotein cholesterol (LDL-C), which may reduce the development of atherosclerosis. Anacetrapib has not been approved for sale in Canada or the United States. Clinical evidence to support the use of anacetrapib for dyslipidemia has been reported in two clinical trials. REVEAL is an ongoing, large-scale phase 3 trial evaluating the effectiveness of anacetrapib with a statin for the secondary prevention of major coronary events in patients who have a history of cardiovascular disease. Results are anticipated in January 2017.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholesteryl ester transfer protein 15	Inhibitor 8,297		17.2 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypercholesterolemia 47	Primary		Phase III 656	Unknown

C_max

Value	Dose	Analyte	Population
5064 nM	400 mg single, oral	ANACETRAPIB plasma	Homo sapiens
3959 nM	200 mg single, oral	ANACETRAPIB plasma	Homo sapiens
1498 nM	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
2421 nM	100 mg single, oral	ANACETRAPIB plasma	Homo sapiens
972 nM	25 mg single, oral	ANACETRAPIB plasma	Homo sapiens
561 nM	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
788 nM	500 mg single, oral	ANACETRAPIB plasma	Homo sapiens
860 nM	250 mg single, oral	ANACETRAPIB plasma	Homo sapiens
168 nM	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
731 nM	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
414 nM	50 mg single, oral	ANACETRAPIB plasma	Homo sapiens
246 nM	25 mg single, oral	ANACETRAPIB plasma	Homo sapiens
145 nM	10 mg single, oral	ANACETRAPIB plasma	Homo sapiens
56 nM	5 mg single, oral	ANACETRAPIB plasma	Homo sapiens
24 nM	2 mg single, oral	ANACETRAPIB plasma	Homo sapiens
9140 nM	800 mg single, oral	ANACETRAPIB plasma	Homo sapiens
889 nM	1000 mg single, oral	ANACETRAPIB plasma	Homo sapiens
3.45 μM	300 mg 1 times / day multiple, oral	ANACETRAPIB plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
82 μM × h	400 mg single, oral	ANACETRAPIB plasma	Homo sapiens
44 μM × h	200 mg single, oral	ANACETRAPIB plasma	Homo sapiens
23.9 μM × h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
34.2 μM × h	100 mg single, oral	ANACETRAPIB plasma	Homo sapiens
10.7 μM × h	25 mg single, oral	ANACETRAPIB plasma	Homo sapiens
9 μM × h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
15.7 μM × h	500 mg single, oral	ANACETRAPIB plasma	Homo sapiens
14 μM × h	250 mg single, oral	ANACETRAPIB plasma	Homo sapiens
4 μM × h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
9.9 μM × h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
5.3 μM × h	50 mg single, oral	ANACETRAPIB plasma	Homo sapiens
2.9 μM × h	25 mg single, oral	ANACETRAPIB plasma	Homo sapiens
2 μM × h	10 mg single, oral	ANACETRAPIB plasma	Homo sapiens
0.68 μM × h	5 mg single, oral	ANACETRAPIB plasma	Homo sapiens
0.26 μM × h	2 mg single, oral	ANACETRAPIB plasma	Homo sapiens
117.4 μM × h	800 mg single, oral	ANACETRAPIB plasma	Homo sapiens
13.6 μM × h	1000 mg single, oral	ANACETRAPIB plasma	Homo sapiens
34.95 μM × h	300 mg 1 times / day multiple, oral	ANACETRAPIB plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
61.5 h	400 mg single, oral	ANACETRAPIB plasma	Homo sapiens
50.9 h	200 mg single, oral	ANACETRAPIB plasma	Homo sapiens
54.4 h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
62 h	100 mg single, oral	ANACETRAPIB plasma	Homo sapiens
42.2 h	25 mg single, oral	ANACETRAPIB plasma	Homo sapiens
50.2 h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
60 h	500 mg single, oral	ANACETRAPIB plasma	Homo sapiens
44.2 h	250 mg single, oral	ANACETRAPIB plasma	Homo sapiens
55.7 h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
46.1 h	125 mg single, oral	ANACETRAPIB plasma	Homo sapiens
34.5 h	50 mg single, oral	ANACETRAPIB plasma	Homo sapiens
28.7 h	25 mg single, oral	ANACETRAPIB plasma	Homo sapiens
28.88 h	10 mg single, oral	ANACETRAPIB plasma	Homo sapiens
21 h	5 mg single, oral	ANACETRAPIB plasma	Homo sapiens
9.3 h	2 mg single, oral	ANACETRAPIB plasma	Homo sapiens
82.6 h	800 mg single, oral	ANACETRAPIB plasma	Homo sapiens
61.9 h	1000 mg single, oral	ANACETRAPIB plasma	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
1000 mg single, oral Highest studied dose	healthy, ADULT
300 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY10537	https://www.001chemical.com/chem/search?q=DY10537
1PlusChem LLC	1P0039O1	https://www.1pchem.com/search?query=1P0039O1
A2B Chem	AB51697	http://a2bchem.com/prod/AB51697
AA Blocks	AA00394L	http://aablocks.com/goods/Goods/detail?id=AA00394L
AChemBlock	C-3348	http://www.achemblock.com/catalogsearch/result/?q=C-3348

Showing 1 to 5 of 45 entries

Previous1 2 3 4 5…9Next

PubMed

Show entries

Title	Date	PubMed
		25824513
The end of the road for CETP inhibitors after torcetrapib?	2009 Jul	19522058
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.	2009 Oct	19843057
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.	2009 Oct	19781408
Raising HDL cholesterol in women.	2010 Aug 9	21072287

Showing 1 to 5 of 8 entries

Previous1 2Next

Patents

Sample Use Guides

In Vivo Use Guide

tablet, 100mg daily

Route of Administration: Oral

In Vitro Use Guide

Anacetrapib (0.1 to 10 uM) dose-dependently inhibited pre-β-HDL formation in vitro in human plasma

Show entries

Name

Type

Language

ANACETRAPIB

Official Name

English

MK0859

Code

English

anacetrapib [INN]

Common Name

English

2-OXAZOLIDINONE, 5-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-3-((4'-FLUORO-2'-METHOXY-5'-(1-METHYLETHYL)-4-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)METHYL)-4-METHYL-, (4S,5R)-

Common Name

English

ANACETRAPIB [USAN]

Common Name

English

Showing 1 to 5 of 11 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Pharmacologic Substance

NCI_THESAURUS

C471

Agent Affecting Digestive System or Metabolism

NCI_THESAURUS

C29703

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Code System

Code

Type

Description

NCI_THESAURUS

C75251

PRIMARY

SMS_ID

100000128110

PRIMARY

EPA CompTox

DTXSID90236452

PRIMARY

EVMPD

SUB34824

PRIMARY

WIKIPEDIA

ANACETRAPIB

PRIMARY

Showing 1 to 5 of 14 entries

Previous1 2 3Next

ACTIVE MOIETY


					P7T269PR6S

ANACETRAPIB

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Doses

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2